These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15285873)

  • 21. [Eosinophils and related diseases].
    Di YW; Liu YH; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):499-502. PubMed ID: 19781208
    [No Abstract]   [Full Text] [Related]  

  • 22. [A case of rectal gastrointestinal stromal tumor in an elderly patient who was successfully treated with imatinib mesylate with no significant adverse events].
    Gomi K; Mihara M; Abe M; Ikeda Y; Shimada K; Maruyama K; Kajikawa S; Shirota H
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):103-6. PubMed ID: 24423962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patent news.
    Steele P; Sparrowhawk M
    IDrugs; 2003 Dec; 6(12):1195-7. PubMed ID: 14712831
    [No Abstract]   [Full Text] [Related]  

  • 24. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
    Kantarjian H; Talpaz M; O'Brien S; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Shan J; Rios MB; Champlin R; de Lima M; Cortes J
    Cancer; 2005 May; 103(10):2099-108. PubMed ID: 15830345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major response to imatinib mesylate in KIT-mutated melanoma.
    Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
    J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
    [No Abstract]   [Full Text] [Related]  

  • 26. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
    Peggs K; Mackinnon S
    N Engl J Med; 2003 Mar; 348(11):1048-50. PubMed ID: 12637616
    [No Abstract]   [Full Text] [Related]  

  • 27. Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital.
    Usman M; Kakepoto GN; Adil SN; Sajid R; Arain S; Khurshid M
    J Pak Med Assoc; 2004 Jan; 54(1):17-20. PubMed ID: 15058636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib results in better quality of life for CML patients than interferon/Ara-C.
    J Support Oncol; 2003; 1(1):77. PubMed ID: 15352651
    [No Abstract]   [Full Text] [Related]  

  • 29. Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
    Wolf D
    Eur J Haematol; 2015 Mar; 94(3):189-90. PubMed ID: 25712068
    [No Abstract]   [Full Text] [Related]  

  • 30. Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?
    Hohenberger P
    Nat Clin Pract Oncol; 2008 May; 5(5):240-1. PubMed ID: 18349856
    [No Abstract]   [Full Text] [Related]  

  • 31. Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes.
    Gotta V; Buclin T; Csajka C; Widmer N
    Ther Drug Monit; 2013 Apr; 35(2):150-67. PubMed ID: 23503441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of different adjuvant therapies for 9 resectable cancer types.
    Kruse M; Parthan A; Coombs J; Sasane M; Taylor D
    Postgrad Med; 2013 Mar; 125(2):83-91. PubMed ID: 23816774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Imatinib for pulmonary arterial hypertension].
    Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
    [No Abstract]   [Full Text] [Related]  

  • 35. Soft tissue calcification secondary to imatinib mesylate in a patient with gastrointestinal stromal tumor.
    Enck RE; Abushahin F; Bossaer JB
    J Oncol Pharm Pract; 2014 Apr; 20(2):137-40. PubMed ID: 23676509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib: the promise of a "magic bullet" for cancer fulfilled.
    Henderson CA
    J Med Assoc Ga; 2003; 92(1):12-4, 22. PubMed ID: 12743899
    [No Abstract]   [Full Text] [Related]  

  • 37. Preserving fertility during cancer treatment.
    Woodruff TK
    Nat Med; 2009 Oct; 15(10):1124-5. PubMed ID: 19812566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
    Kantarjian HM; O'Brien S; Cortes JE; Smith TL; Rios MB; Shan J; Yang Y; Giles FJ; Thomas DA; Faderl S; Garcia-Manero G; Jeha S; Wierda W; Issa JP; Kornblau SM; Keating M; Resta D; Capdeville R; Talpaz M
    Clin Cancer Res; 2002 Jul; 8(7):2167-76. PubMed ID: 12114417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing GIST in the imatinib era: optimization of adjuvant therapy.
    Trent JC; Subramanian MP
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.